ADMA Biologics, Inc. (ADMA) Q2 2024 Earnings Call Transcript
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and CEO Brad Tade - Vice President, Financial Operations Conference Call Participants Anthony Petrone - Mizuho Americas Rick Miller - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon, and welcome to the ADMA Biologics Second Quarter 2024 Financial Results and Business Update Conference Call on Thursday, August 08, 2024. At this time, all participants are in a listen-only mode.
Adma Biologics (ADMA) Surpasses Q2 Earnings and Revenue Estimates
Adma Biologics (ADMA) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago.
Adma Biologics (ADMA) Rises But Trails Market: What Investors Should Know
In the latest trading session, Adma Biologics (ADMA) closed at $12.28, marking a +0.82% move from the previous day.
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
In the latest trading session, Adma Biologics (ADMA) closed at $12.18, marking a -1.46% move from the previous day.
ADMA Biologics: A Compelling GARP Stock For Biotech Investors
ADMA Biologics focuses on developing and commercializing plasma-derived products, primarily targeting immune-compromised patients. Revenue streams come from FDA-approved products, immunotechnology, and CDMO services, with a promising US immunoglobulin market. The company's IP portfolio includes three FDA-approved drugs: Asceniv, Bivigam, and Nabi-HB.
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors
Adma Biologics (ADMA) reachead $13.05 at the closing of the latest trading day, reflecting a -1.81% change compared to its last close.
Add These 5 Hot Biotech Stocks In July
Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you're investing in companies that are working to treat or heal medical ailments that cause issues for people around the world.
5 Stocks With Recent Price Strength to Tap Wall Street Rally
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, AMSC, BTMD, LINC, CORT.
3 Millionaire-Making Stock Picks With Astounding Growth Potential
Finding millionaire-making stocks is not easy. While we can't tell the future, we can do the next best thing: think forward, gauge a company's room for growth, and determine how it intends to reach the next level.
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
Here is how Adma Biologics (ADMA) and Aclaris Therapeutics (ACRS) have performed compared to their sector so far this year.
